VRAX (Virax Biolabs Group) Tariff Resilience Score: 5/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRAX Virax Biolabs Group Ltd VRAX
44 GF Score
Price $3.84
GF Value $3.63
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Virax Biolabs Group Tariff Resilience Score?

Virax Biolabs Group VRAX +1.32% 44 Tariff Resilience Score is 5 as of Jul. 20, 2026. GuruFocus rates VRAX with a GF Score™ of 44/100 and a GF Value™ of $3.63 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, Virax Biolabs Group ranks better than 62.41% on this metric.

Virax Biolabs Group has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Virax Biolabs Group has Biotech company with international supply chains for lab equipment and materials. Vulnerable to tariffs but can leverage industry-specific exemptions and alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Virax Biolabs Group might have Average Resilient.

Virax Biolabs Group  (NAS:VRAX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Virax Biolabs Group Tariff Resilience Score Related Terms

VRAX vs BBLG, PKTX, OGEN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Virax Biolabs Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Tariff Resilience Score falls into.


VRAX
44GF Score
Virax Biolabs Group Ltd VRAX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Virax Biolabs Group (VRAX) has a Tariff Resilience Score of 5 as of Jul. 20, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Virax Biolabs Group ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Virax Biolabs Group's Tariff Resilience Score too high?
Virax Biolabs Group's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Virax Biolabs Group's value of 5 is 25% above this industry median. Based on the distribution chart, Virax Biolabs Group ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Virax Biolabs Group has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Tariff Resilience Score compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #515 out of 1370 companies for Tariff Resilience Score. This puts Virax Biolabs Group in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Virax Biolabs Group's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.63, compared to a current price of $3.84 — trading 5.8% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Virax Biolabs Group's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Tariff Resilience Score is 5 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.84 is trading 5.8% above its estimated GF Value™ of $3.63. GuruFocus considers Virax Biolabs Group to be Fairly Valued.

Key valuation signals for VRAX:

  • Tariff Resilience Score: 5
  • GF Value™: $3.63 vs. price of $3.84 (5.8% above fair value)
  • GF Score™: 44/100 with 3 warning signs
  • Industry Position: 25% above the Biotechnology median (#515 of 1370)

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
44GF Score

Get the complete analysis for VRAX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price
$3.63
GF Value